50.5% achieved 15% or more STEP 2 (1,210 adults with T2D): 9.6% mean weight loss STEP 3 (with behavioral therapy): 16.0% mean weight loss STEP 5 (2-year data): 15.2% sustained weight loss at 104 weeks Zovaglutide (Phase 2)# Zovaglutide Phase 2 results (presented at EASD 2025) enrolled 303 overweight or obese adults across five dose arms over 24 weeks: Cross-Trial Comparison (Important Caveats)# Zovaglutide's Phase 2 results (10.6-14.4% at 24 weeks) suggest a competitive weight loss trajectory, but several critical differences preclude direct comparison: Duration : 24 weeks (zovaglutide) vs 68 weeks (semaglutide STEP 1)
Like any form, it supports fat metabolism as a shuttle for fatty acids it doesn't independently cause weight loss
Learn more about how we help with semaglutide or book an appointment to get started
The purpose of this article is to review the mechanism of action of GLP-1 receptor agonists in type 2 diabetes and discuss the available treatment options in this drug class, including key clinical benefits, safety considerations, and practical information about patient selection, education, prescribing, and safety monitoring
The FDA oversees device approvals and recalls
doi: 10.1111/fcp.12329 205 WangXWangLJiangRYuanYYuQLiY